Evaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer.

Published on May 1, 2017in Nuclear Medicine and Biology2.396
· DOI :10.1016/J.NUCMEDBIO.2017.01.002
Giuseppe Carlucci27
Estimated H-index: 27
(MSK: Memorial Sloan Kettering Cancer Center),
Brandon Carney9
Estimated H-index: 9
(CUNY: City University of New York)
+ 3 AuthorsThomas Reiner39
Estimated H-index: 39
(Cornell University)
Abstract Rationale Ataxia telangiectasia and Rad3-related (ATR) threonine serine kinase is one of the key elements in orchestrating the DNA damage response (DDR). As such, inhibition of ATR can amplify the effects of chemo- and radiation-therapy, and several ATR inhibitors (ATRi) have already undergone clinical testing in cancer. For more accurate patient selection, monitoring and staging, real-time in vivo imaging of ATR could be invaluable; the development of appropriate imaging agents has remained a major challenge. Methods 3-amino- N -(4-[ 18 F]phenyl)-6-(4-(methylsulfonyl)phenyl)pyrazine-2-carboxamide ([ 18 F]-ATRi), a close analogue of Ve-821, (a clinical ATRi candidate), was readily accomplished similarly to already established synthetic procedures. Structurally, 18 F was introduced at the 4-position of the aromatic ring of Ve-821 for generating a labeled ATR inhibitor. In vitro experiments were conducted in U251 MG glioblastoma cell lines and ex vivo biodistribution were performed in subcutaneous U251 MG xenograft bearing athymic nude mice following microPET imaging. Results [ 18 F]-ATRi has a similar pharmacokinetic profile to that of Ve-821. Using an U251 MG glioblastoma mouse model, we evaluated the in vivo binding efficiency of [ 18 F]-ATRi. Blood and tumor showed a statistically significant difference between mice injected with only the probe or following blocking experiment with Ve-821 (1.48 ± 0.40%ID/g vs. 0.46 ± 0.12%ID/g in tumor and 1.85 ± 0.47%ID/g vs. 0.84 ± 0.3%ID/g in blood respectively). Conclusions [ 18 F]-ATRi represents the first 18 F positron emission tomography (PET) ATR imaging agent, and is designed on a low nanomolar and clinically relevant ATR inhibitor.
📖 Papers frequently viewed together
10 Citations
#1Stephen P. Jackson (Wellcome Trust/Cancer Research UK Gurdon Institute)H-Index: 144
#2Thomas Helleday (Science for Life Laboratory)H-Index: 80
All the cells in our bodies suffer many thousands of DNA lesions every day ( 1 ). The vast majority of these lesions are safely dealt with by cellular DNA repair and associated DNA damage response (DDR) activities that are, as a consequence, vital for life. Defects in or deregulation of our DNA repair/DDR systems are linked to many human pathologies ( 2 ). Yet, perhaps counterintuitively, pharmacological inhibitors of DNA repair/DDR have considerable potential in treating various human diseases,...
46 CitationsSource
#1Brandon Carney (CUNY: City University of New York)H-Index: 9
#2Giuseppe Carlucci (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 27
Last. Thomas Reiner (Cornell University)H-Index: 39
view all 12 authors...
The current study presents [(18)F]PARPi as imaging agent for PARP1 expression.[(18)F]PARPi was generated by conjugating a 2H-phthalazin-1-one scaffold to 4-[(18)F]fluorobenzoic acid. Biochemical assays, optical in vivo competition, biodistribution analysis, positron emission tomography (PET)/X-ray computed tomography, and PET/magnetic resonance imaging studies were performed in subcutaneous and orthotopic mouse models of glioblastoma.[(18)F]PARPi shows suitable pharmacokinetic properties for bra...
40 CitationsSource
#1Marwan Kwok (University of Birmingham)H-Index: 7
#2Nicholas J. Davies (University of Birmingham)H-Index: 14
Last. Tatjana Stankovic (University of Birmingham)H-Index: 38
view all 15 authors...
TP53 and ataxia telangiectasia mutated (ATM) defects are associated with genomic instability, clonal evolution, and chemoresistance in chronic lymphocytic leukemia (CLL). Currently, therapies capable of providing durable remissions in relapsed/refractory TP53- or ATM-defective CLL are lacking. Ataxia telangiectasia and Rad3-related (ATR) mediates response to replication stress, the absence of which leads to collapse of stalled replication forks into chromatid fragments that require resolution th...
131 CitationsSource
#1Ching Chia Li (KMU: Kaohsiung Medical University)H-Index: 13
#2Juan-Cheng Yang (PRC: China Medical University (PRC))H-Index: 9
Last. Yang Chang Wu (PRC: China Medical University (PRC))H-Index: 70
view all 11 authors...
DNA damage responses contribute to cisplatin resistance; however, therapeutic strategies to overcome cisplatin resistance have not yet been established. Here, we demonstrate that inhibition of ATR-Chk1 pathway with the potent inhibitor WYC0209 sensitizes bladder cancer cells to cisplatin. In the clinical microarray profile, high ATR expression is associated with poor prognosis in bladder cancer patients who receive chemotherapy. We show that pharmacological and genetic suppressing of ATR sensiti...
15 CitationsSource
#1Robin G. Lerner (UCSF: University of California, San Francisco)H-Index: 6
#2Stefan Grossauer (UCSF: University of California, San Francisco)H-Index: 5
Last. Claudia Petritsch (UCSF: University of California, San Francisco)H-Index: 22
view all 13 authors...
The treatment of glioblastoma (GBM) remains challenging in part due to the presence of stem-like tumor-propagating cells that are resistant to standard therapies consisting of radiation and temozolomide. Among the novel and targeted agents under evaluation for the treatment of GBM are BRAF/MAPK inhibitors, but their effects on tumor-propagating cells are unclear. Here, we characterized the behaviors of CD133+ tumor-propagating cells isolated from primary GBM cell lines. We show that CD133+ cells...
23 CitationsSource
#1Larry M. Karnitz (Mayo Clinic)H-Index: 46
#2Lee Zou (Harvard University)H-Index: 53
The human ATR gene encodes a kinase that is activated by DNA damage and replication stress as a central transducer of a checkpoint signaling pathway. Once activated, ATR phosphorylates multiple substrates, including the kinase Chk1, to regulate cell-cycle progression, replication fork stability, and DNA repair. These events promote cell survival during replication stress and in cells with DNA damage. Accordingly, there has been the tantalizing possibility that ATR inhibitors would be therapeutic...
138 CitationsSource
#1Shafiq U. Ahmed (Glas.: University of Glasgow)H-Index: 14
#2Ross Carruthers (Glas.: University of Glasgow)H-Index: 9
Last. Anthony J. Chalmers (Glas.: University of Glasgow)H-Index: 32
view all 6 authors...
Glioblastoma is the most common form of primary brain tumor in adults and is essentially incurable. Despite aggressive treatment regimens centered on radiotherapy, tumor recurrence is inevitable and is thought to be driven by glioblastoma stem-like cells (GSC) that are highly radioresistant. DNA damage response pathways are key determinants of radiosensitivity but the extent to which these overlapping and parallel signaling components contribute to GSC radioresistance is unclear. Using a panel o...
95 CitationsSource
#1Jan Benada (CAS: Academy of Sciences of the Czech Republic)H-Index: 6
#2Libor Macurek (CAS: Academy of Sciences of the Czech Republic)H-Index: 20
Cancer treatments such as radiotherapy and most of the chemotherapies act by damaging DNA of cancer cells. Upon DNA damage, cells stop proliferation at cell cycle checkpoints, which provides them time for DNA repair. Inhibiting the checkpoint allows entry to mitosis despite the presence of DNA damage and can lead to cell death. Importantly, as cancer cells exhibit increased levels of endogenous DNA damage due to an excessive replication stress, inhibiting the checkpoint kinases alone could act a...
74 CitationsSource
#1Anika M. Weber (Medical Research Council)H-Index: 6
#2Anderson J. Ryan (Medical Research Council)H-Index: 48
Abstract In order to maintain genomic stability, cells have developed sophisticated signalling pathways to enable DNA damage or DNA replication stress to be resolved. Key mediators of this DNA damage response (DDR) are the ATM and ATR kinases, which induce cell cycle arrest and facilitate DNA repair via their downstream targets. Inhibiting the DDR has become an attractive therapeutic concept in cancer therapy, since (i) resistance to genotoxic therapies has been associated with increased DDR sig...
317 CitationsSource
#1Tarek M. A. Abdel-Fatah (University of Nottingham)H-Index: 20
#2Fiona K. Middleton (Newcastle University)H-Index: 7
Last. Srinivasan Madhusudan (University of Nottingham)H-Index: 41
view all 15 authors...
Background: ATR-Chk1 signalling network is critical for genomic stability. ATR-Chk1 may be deregulated in breast cancer and have prognostic, predictive and therapeutic significance. Patients and methods: We investigated ATR and phosphorylated CHK1Ser345 protein (pChk1) expression in 1712 breast cancers (Nottingham Tenovus series). ATR and Chk1 mRNA were evaluated in 1950 breast cancers (METABRIC cohort). Pre-clinically, biological consequences of ATR gene knockdown or ATR inhibition by small mol...
49 CitationsSource
Cited By3
#1Laura Puentes (UPenn: University of Pennsylvania)H-Index: 4
#2Mehran Makvandi (UPenn: University of Pennsylvania)H-Index: 14
Last. Robert H. Mach (UPenn: University of Pennsylvania)H-Index: 60
view all 3 authors...
The genetic code to life is balanced on a string of DNA that is under constant metabolic and physical stress from environmental forces. Nearly all diseases have a genetic component caused by or resulting in DNA damage that alters biology to drive pathogenesis. Recent advancements in DNA repair biology have led to the development of imaging tools that target DNA damage response and repair proteins. Positron-emission tomography (PET) has been used for early detection of oncogenic processes and mon...
#1Loredana G. Marcu (UniSA: University of South Australia)H-Index: 17
#2Leyla Moghaddasi (University of Adelaide)H-Index: 4
Last. Eva Bezak (University of Adelaide)H-Index: 21
view all 3 authors...
Purpose Improvements in personalized therapy are made possible by the advances in molecular biology that led to developments in molecular imaging, allowing highly specific in vivo imaging of biological processes. Positron emission tomography (PET) is the most specific and sensitive imaging technique for in vivo molecular targets and pathways, offering quantification and evaluation of functional properties of the targeted anatomy. Materials and Methods This work is an integrative research review ...
16 CitationsSource
#1Anna A. Rybczynska (UG: University of Groningen)H-Index: 11
#2Hendrikus H. Boersma (UG: University of Groningen)H-Index: 26
Last. Aren van Waarde (UMCG: University Medical Center Groningen)H-Index: 18
view all 8 authors...
Successful treatment of cancer patients requires balancing of the dose, timing, and type of therapeutic regimen. Detection of increased cell death may serve as a predictor of the eventual therapeutic success. Imaging of cell death may thus lead to early identification of treatment responders and nonresponders, and to patient-tailored therapy. Cell death in organs and tissues of the human body can be visualized, using positron emission tomography or single-photon emission computed tomography, alt...
15 CitationsSource